ET-019002

N/A

Report date: 2025/09/12 20:01:19

Base Information

Drug NameET-019002
Drug Alias NameET019002-T Cell TherapyET019002-T CellsET-019002
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionGene transferenceImmunologic cytotoxicityT lymphocyte replacements +[4] 
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLymphoma, FollicularLymphoma, Large B-Cell, DiffuseLymphoma, B-Cell +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesEureka Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesEureka Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsLymphoma, FollicularLymphoma, Large B-Cell, DiffuseBurkitt Lymphoma
Inactive IndicationsLymphoma, B-CellLeukemia, B-Cell

Other Information

ATC CodeN/A
Related LinksN/A